May 2022: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
Digestive and Biliary Disorders
Durvalumab Plus Chemo Granted Priority Review for Biliary Tract Cancer
The sBLA was supported by data from the phase 3 TOPAZ-1 trial.
Guidelines Updated for Barrett Esophagus Diagnosis, Management
Guideline revised to synthesize current best practices in the management of Barrett esophagus
GLP-1 RA Use May Up Risk for Gallbladder, Biliary Diseases
GLP-1 RA treatment linked to increased risk, especially in trials for weight loss, and with higher doses and longer duration of use
Adding Immunotherapy to Chemo Ups Survival in Advanced Biliary Tract Cancer
Overall survival, progression-free survival prolonged in those receiving durvalumab versus placebo in addition to gemcitabine and cisplatin
Immune-Modifying Nanoparticle Therapy Fast Tracked for Primary Biliary Cholangitis
The treatment is expected to reprogram the immune system to induce tolerance to PDC-E2.
Livmarli Approved for Cholestatic Pruritus in Alagille Syndrome
The approval was based on data from the phase 2b ICONIC study, along with 5 years of data from supportive studies.
Long-Acting Octreotide Therapy Gets Orphan Drug Status for Polycystic Liver Disease
CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot.
Bylvay Approved for Progressive Familial Intrahepatic Cholestasis
Bylvay is an oral reversible inhibitor of the ileal bile acid transporter.
Devimistat Granted Orphan Drug Status for Biliary Cancer
Devimistat targets the mitochondrial tricarboxylic acid cycle selectively in cancer cells.
